COMPASS Pathways earns repeat ‘Buy' rating and US$60 price target on adjusted trial design for COMP360Proactive Investors • 03/13/23
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull MarketThe Motley Fool • 03/06/23
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor ConferenceGlobeNewsWire • 03/02/23
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business HighlightsGlobeNewsWire • 02/28/23
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023GlobeNewsWire • 02/24/23
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall StreetThe Motley Fool • 02/07/23
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong BuyZacks Investment Research • 01/13/23
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNPGlobeNewsWire • 12/08/22
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/28/22
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of MedicineGlobeNewsWire • 11/03/22
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022GlobeNewsWire • 10/26/22
COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/25/22
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets DayGlobeNewsWire • 10/12/22